Uncovering the Complexities of Drug Bans in India: Are Key Considerations Being Overlooked?
The use of fixed dose combinations (FDCs) in healthcare has significant public health implications, both positive and negative. Positive aspects include simplifying treatment regimens, improving patient adherence, and cost-effectiveness, particularly in resource-constrained settings. However, negati...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-11-01
|
| Series: | Medical Journal of Dr. D.Y. Patil Vidyapeeth |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/mjdrdypu.mjdrdypu_889_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850245975320297472 |
|---|---|
| author | Samiksha Bhattacharjee Sudip Bhattacharya |
| author_facet | Samiksha Bhattacharjee Sudip Bhattacharya |
| author_sort | Samiksha Bhattacharjee |
| collection | DOAJ |
| description | The use of fixed dose combinations (FDCs) in healthcare has significant public health implications, both positive and negative. Positive aspects include simplifying treatment regimens, improving patient adherence, and cost-effectiveness, particularly in resource-constrained settings. However, negative implications arise when FDCs are used without careful consideration, leading to irrational combinations, reduced treatment options, and potential overuse. Moreover, substandard FDCs and aggressive marketing can pose risks, such as antibiotic resistance and treatment failures. Mitigating the negative implications of FDCs requires a comprehensive strategy. Strengthening regulatory oversight, rigorous approval processes, and clear scientific evidence for FDCs’ benefits over single-drug formulations are essential. Transparency in the approval process, regular reviews, and postmarketing surveillance hold regulatory agencies accountable. Training and education for healthcare professionals, emphasizing evidence-based decision-making, and encouraging adverse event reporting can help ensure rational use. Pharmacovigilance programs, clinical practice guidelines, and national formularies aid in monitoring and guiding FDC use. Public awareness campaigns and patient engagement foster informed discussions and reporting. Research and development efforts should focus on optimizing FDC formulations and assessing cost-effectiveness. International collaboration to harmonize standards and prevent substandard FDCs’ global spread is crucial. Legal measures should be in place to deter misleading marketing and distribution of unsafe FDCs by pharmaceutical companies. In conclusion, addressing the negative implications of FDCs involves a multifaceted approach that spans healthcare professionals, regulators, pharmaceutical companies, and the public. By ensuring rational and safe use, FDCs can maximize their benefits while minimizing associated risks in the realm of public health. |
| format | Article |
| id | doaj-art-3ff9e23e10f24f4a9ab61117964fdbdf |
| institution | OA Journals |
| issn | 2589-8302 2589-8310 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Medical Journal of Dr. D.Y. Patil Vidyapeeth |
| spelling | doaj-art-3ff9e23e10f24f4a9ab61117964fdbdf2025-08-20T01:59:17ZengWolters Kluwer Medknow PublicationsMedical Journal of Dr. D.Y. Patil Vidyapeeth2589-83022589-83102024-11-011761149115310.4103/mjdrdypu.mjdrdypu_889_23Uncovering the Complexities of Drug Bans in India: Are Key Considerations Being Overlooked?Samiksha BhattacharjeeSudip BhattacharyaThe use of fixed dose combinations (FDCs) in healthcare has significant public health implications, both positive and negative. Positive aspects include simplifying treatment regimens, improving patient adherence, and cost-effectiveness, particularly in resource-constrained settings. However, negative implications arise when FDCs are used without careful consideration, leading to irrational combinations, reduced treatment options, and potential overuse. Moreover, substandard FDCs and aggressive marketing can pose risks, such as antibiotic resistance and treatment failures. Mitigating the negative implications of FDCs requires a comprehensive strategy. Strengthening regulatory oversight, rigorous approval processes, and clear scientific evidence for FDCs’ benefits over single-drug formulations are essential. Transparency in the approval process, regular reviews, and postmarketing surveillance hold regulatory agencies accountable. Training and education for healthcare professionals, emphasizing evidence-based decision-making, and encouraging adverse event reporting can help ensure rational use. Pharmacovigilance programs, clinical practice guidelines, and national formularies aid in monitoring and guiding FDC use. Public awareness campaigns and patient engagement foster informed discussions and reporting. Research and development efforts should focus on optimizing FDC formulations and assessing cost-effectiveness. International collaboration to harmonize standards and prevent substandard FDCs’ global spread is crucial. Legal measures should be in place to deter misleading marketing and distribution of unsafe FDCs by pharmaceutical companies. In conclusion, addressing the negative implications of FDCs involves a multifaceted approach that spans healthcare professionals, regulators, pharmaceutical companies, and the public. By ensuring rational and safe use, FDCs can maximize their benefits while minimizing associated risks in the realm of public health.https://journals.lww.com/10.4103/mjdrdypu.mjdrdypu_889_23fixed drug combinationpharmacovigilancepublic health |
| spellingShingle | Samiksha Bhattacharjee Sudip Bhattacharya Uncovering the Complexities of Drug Bans in India: Are Key Considerations Being Overlooked? Medical Journal of Dr. D.Y. Patil Vidyapeeth fixed drug combination pharmacovigilance public health |
| title | Uncovering the Complexities of Drug Bans in India: Are Key Considerations Being Overlooked? |
| title_full | Uncovering the Complexities of Drug Bans in India: Are Key Considerations Being Overlooked? |
| title_fullStr | Uncovering the Complexities of Drug Bans in India: Are Key Considerations Being Overlooked? |
| title_full_unstemmed | Uncovering the Complexities of Drug Bans in India: Are Key Considerations Being Overlooked? |
| title_short | Uncovering the Complexities of Drug Bans in India: Are Key Considerations Being Overlooked? |
| title_sort | uncovering the complexities of drug bans in india are key considerations being overlooked |
| topic | fixed drug combination pharmacovigilance public health |
| url | https://journals.lww.com/10.4103/mjdrdypu.mjdrdypu_889_23 |
| work_keys_str_mv | AT samikshabhattacharjee uncoveringthecomplexitiesofdrugbansinindiaarekeyconsiderationsbeingoverlooked AT sudipbhattacharya uncoveringthecomplexitiesofdrugbansinindiaarekeyconsiderationsbeingoverlooked |